ClinicalTrials.gg
RecruitingNCT05048602Updated Sep 17, 2021

Drug-induced Brugada Syndrome Research Database

An observational study in Brugada Syndrome, Arrhythmia and ICD, sponsored by University of Campania Luigi Vanvitelli. Recruiting at 1 site in Italy. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.

Sponsored by University of Campania Luigi Vanvitelli · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Brugada Syndrome with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Brugada Syndrome · Italy.

Started
2021
with 1 other
Observational
6 of 12
2 open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
University of Campania Luigi Vanvitelli

Among the 12 studies in Brugada Syndrome with a site in Italy, this one is one of 2 that started in 2021, is one of 6 observational ones, and was the 8th registered.

Brugada Syndrome

53 studies on the registry are indexed under Brugada Syndrome; 19 are open to participants now.

Browse Brugada Syndrome studies →

Open to participants now

5 of the 12 studies in Brugada Syndrome with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 15 Brugada Syndrome studies recruiting now, 10 (67%) set no upper age limit and none (0%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 16 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Brugada Syndrome with a site in Italy, or all of them as a file.
02

Study summary

All patients with drug-induced Brugada syndrome who are evaluated and followed at each participating centers will be recorded in this register. Within this register a characterization of patients and therapy will be done. Prognostic factors of adefined clinical relevant endpoints will be evaluated.

03

Conditions studied

  • Brugada Syndrome
  • Arrhythmia
  • ICD
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with drug-induced Brudaga Syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All consecutive patients with drug-induced Brugada Syndrome

Exclusion criteria

Exclusion Criteria:

  • Missing Form
  • Missing Contact Informations for Follow up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Sudden Cardiac Death

    Unexpected death due to cardiac causes that occurs in a short time period.

    Time frame: 1 year

  2. Appropriate ICD Therapies

    Antitachycardia pacing therapy or shock delivered by ICD for device detected ventricular arrhythmia

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Sep 2023, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2021
First posted
Sep 17, 2021
StartActual
Sep 7, 2021
Primary completionEst.
Sep 7, 2023
CompletionEst.
Sep 7, 2025
Last update
Sep 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05048602
Responsible party
Vincenzo Russo (Principal Investigator, University of Campania Luigi Vanvitelli) — Principal investigator
First posted
Sep 17, 2021
Start date
Sep 7, 2021
Primary completion
Sep 7, 2023 (estimated)
Completion
Sep 7, 2025 (estimated)
Last update
Sep 17, 2021

Study contacts

Vincenzo Russo, MD PhD
Contact
vincenzo.russo@unicampania.it
+390817062355
Vincenzo Russo, MD PhD
study chair · University of Campania Luigi Vanvitelli

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion